Liu Minling, Fang Shuo, Dai Huiru, Li Tingwei, Guo Chunyan, Wang Bo
Department of Oncology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
Case Rep Oncol. 2025 Jun 11;18(1):912-919. doi: 10.1159/000546423. eCollection 2025 Jan-Dec.
The development of immune-related adverse events (irAEs) has been associated with improved survival from various solid tumors. Given that immunotherapy has not been widely used in ovarian cancer and has only been applied to patients with high tumor mutational burden or microsatellite instability, studies exploring the effects of irAEs on ovarian cancer have been limited.
A 47-year-old woman was diagnosed with International Federation of Gynecology and Obstetrics stage III ovarian cancer in 2013. Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib. However, all antitumor treatments were discontinued from April 2023 due to multiple irAEs, including hypothyroidism, adrenal insufficiency, and pneumonitis, with the tumor remaining stable until November 2023. Progression-free survival (PFS) was approximately 24 months with tislelizumab-containing therapy but was 18 months with tislelizumab/olaparib maintenance therapy.
We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer.
免疫相关不良事件（irAEs）的发生与多种实体瘤患者生存率的提高有关。鉴于免疫疗法尚未在卵巢癌中广泛应用，仅应用于肿瘤突变负荷高或微卫星不稳定的患者，探索irAEs对卵巢癌影响的研究有限。
一名47岁女性于2013年被诊断为国际妇产科联盟III期卵巢癌。在2013年至2021年期间，她接受了包括紫杉醇脂质体、顺铂/奈达铂、S-1/雷替曲塞、伊立替康、阿霉素、长春瑞滨、托瑞帕利单抗、阿帕替尼、吉西他滨、奥沙利铂和卡培他滨在内的姑息化疗，以及两次肿瘤减灭术。从2021年11月起，她接受了六个周期的替雷利珠单抗（一种PD-1抑制剂）、白蛋白结合型紫杉醇和卡铂治疗，根据实体瘤疗效评价标准观察到部分缓解。从2022年5月起，患者改用替雷利珠单抗联合奥拉帕利进行维持治疗。然而，由于包括甲状腺功能减退、肾上腺功能不全和肺炎在内的多种irAEs，所有抗肿瘤治疗于2023年4月停止，肿瘤在2023年11月前保持稳定。含替雷利珠单抗治疗的无进展生存期（PFS）约为24个月，但替雷利珠单抗/奥拉帕利维持治疗的PFS为18个月。
我们报告了一例高度预处理的复发性卵巢癌患者，在出现三种irAEs后PFS延长。观察到的明显延长的PFS以及综述文献表明，irAEs可能与卵巢癌患者生存率的提高相关。
